Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00073125 | Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma | PHASE2 | COMPLETED | 103 | — | — | May 1, 2003 | - | Aug 15, 2007 | 18 | United States, Netherlands |
| Name | Type | Description |
|---|---|---|
| ABT-510/Thrombospondin-1 mimetic | DRUG | - |
Inclusion Criteria: A subject will be eligible for study participation if all of the following criteria are met: * The subject is at least 18 years of age. * The subject has advanced histologically documented renal cell carcinoma. Advanced disease is defined as locally recurrent disease or metasta...